Abstract
In the past, if patients presented with heart failure following MI, clinicians were left with a difficult decision regarding treatment. The evidence in support of various therapies remained equivocal. However, the situation is now clearer as the results of the Acute Infarction Ramipril Efficacy (AIRE) study have demonstrated a significant 27% reduction in mortality in patients receiving the ACE inhibitor ramipril, compared with placebo. The study results were presented at the 15th Congress of the European Society of Cardiology held in Nice, France, last month.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call